Journals / Journal of the Turkish-German Gynecological Association / 2009 / Cilt: 10 - Sayı: 4

İmmünmodülatör ilaç kullanan multiple sklerozlu hastalarda over rezervinin ve Doppler karakteristiklerinin değerlendirilmesi

Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs

Pages
213–219
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further studies are required to elucidate whether compromised ovarian reserve in MS patients is due to drugs or the disease itself.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: There is limited data about fertility in multiple sclerosis (MS) patients using immunomodulating drugs and no data exists regarding the ovarian reserve of these patients.
📊
Key Findings & Data:On the same day, blood was taken for determining serum follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels.
💡
Conclusion & Impact:However, further studies are required to elucidate whether compromised ovarian reserve in MS patients is due to drugs or the disease itself.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: There is limited data about fertility in multiple sclerosis (MS) patients using immunomodulating drugs and no data exists regarding the ovarian reserve of these patients. Therefore, we aimed to evaluate,the ovarian reserve and doppler characteristics of MS patients using immunomodulating drugs. Material and Methods: MS patients using immunomodulating drugs (interferon (IFN) β and glatiramer acetate) and age-matched healthy controls were included in the study. Subjects were examined in the early follicular phase of the menstrual cycle with transvaginal ultrasound to evaluate ovarian volume, antral follicle count (AFC) and ovarian stromal artery Doppler. On the same day, blood was taken for determining serum follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. A subgroup analysis was also carried out between MS patients using only IFN β and controls to compare the same parameters. Results: Mean ovarian volume and total AFC were lower in MS patients using immunomodulating drugs than in the controls. FSH and E2 levels did not show any differences between the groups, but LH levels were significantly higher in MS patients. All the Doppler parameters of the ovarian stromal artery were higher in MS patients but not significantly. In the subgroup analysis, the same significant differences were found for ovarian volume, AFC and LH levels. In addition, MS patients showed significantly higher mean pulsatility index measurement than the controls. Conclusion: The findings of this study demonstrated diminished ovarian volume and follicular reserve in MS patients using immunomodulating drugs compared to age matched healthy controls. However, further studies are required to elucidate whether compromised ovarian reserve in MS patients is due to drugs or the disease itself.

Özet

Amaç: İmmünmodülatör tedavi kullanan Multipl Skleroz (MS) hastalarının fertiliteleriyle ilgili sınırlı, over rezervleriyle ilgili ise hiç data mevcut değildir. Bu çalışmadaki amacımız, immünmodülatör tedavi kullanan MS hastalarının over rezervleri ve stromal arter doppler karakteristiklerini incelemektir. Gereç ve Yöntemler: Çalışmaya immünmodülatör tedavi (interferon-beta ve glatiramer asetat) kullanan MS hastaları ve yaş uyumlu sağlıklı kontrol grubu alındı. Hastalar erken foliküler dönemde transvajinal ultrasonografi ile incelenerek over hacmi, antral folikül sayısı (AFS) ve overyan stromal arter Doppler ölçümleri açısından değerlendirildi. Aynı gün serum folikül stimüle edici hormon (FSH), luteinize edici hormone (LH) ve estradiol (E2 ) ölçümleri için kan alındı. Sadece interferon tedavisi alan hastaları kontrol grbuyla karşılaştırmak için subgrup analizi de yapıldı. Bulgular: İmmünmodülatör tedavi kullanan MS hastalarının ortalama over hacmi ve total AFS ölçümleri kontrol grubuna göre düşük bulundu. Gruplar arası FSH ve E2 seviyeleri bir fark göstermemekle birlikte LH seviyesi MS hastalarında anlamlı olarak yüksekti. Overyan stromal arter Doppler parametrelerinin tümü MS hastalarında yüksekti ancak bu yükseklik anlamlı değildi. Sırf interferon kullanan hastaların dahil edildiği subgrup analizinde, over hacmi, AFS ve LH seviyeleri arasında yine anlamlı fark bulundu. Buna ek olarak interferon kullanan MS hastalarının PI ölçümleri kontrol grubuna göre anlamlı olarak yüksekti. Sonuç: Bu çalışmada immünmodülatör tedavi kullanan MS hastalarının over hacmi ve folikül rezervi aynı yaştaki sağlıklı kontrol grubuna göre daha düşük bulundu. Ancak over rezervindeki bu düşüklüğün MS hastalığına mı, yoksa kullanılan immunmodülatuar tedaviye mi bağlı olduğunun, daha geniş hasta serileriyle araştırılması gerekmektedir.

🔖

Cite This Article

SÖNMEZER, M., ÇİL, A. P., SOYLUKOÇ, R., OKTAY, K., LEVENTOĞLU, A. (2022). İmmünmodülatör ilaç kullanan multiple sklerozlu hastalarda over rezervinin ve Doppler karakteristiklerinin değerlendirilmesi. Journal of the Turkish-German Gynecological Association, Cilt: 10 - Sayı: 4, 213–219. https://ajindex.com/articles/567850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002; 53: 285-302
  2. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995; 118: 253-61
  3. Cavalla P, Rovei V, Masera S, Vercellino M, Massobrio M, Mutani R, et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006; 27: 231-9
  4. Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65: 1961-3
  5. Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Gold R. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008; 118: 24-8
  6. Edan G, Brochet B, Clanet M. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 years follow-up study. Neurology 2004; 62 (Suppl 5): A493. Abstract
  7. Portaccio E, Zipoli V, Siracusa G, Piacentini S, Sorbi S, Amato MP. Safety and tolerability of cyclophosphamide “pulses” in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler 2003; 9: 446-50
  8. Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 00: 1-9
  9. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19-23
  10. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41
  11. Grinsted L, Heltberg A, Hagen C, Djursing H. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J Intern Med. 1989; 226: 241-4
  12. Lotfi J, Zohrevand P, Heshmat A, Sahraian M, Parsi H, Bagheri M. Menstrual disorders in multiple sclerosis patients receiving interferon-beta. Mult Scler 2006;12: S209
  13. Nabvi M, Garshasbi E, Jalali M, Nejati MR. Menstural disturbances and related plasma hormone levels in female multiple sclerosis patients. Mult Scler 2006; 12: S37
  14. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
  15. PRISMS Study Grou